BioCryst climbs on strong sales for swelling disorder treatment
06/05/2024 12:26
** Shares of drugmaker BioCryst Pharmaceuticals BCRX.O
rise ~7.4% to $4.78 premarket
** Co clocks Q1 revenue of $92.8 mln vs analysts' average
estimate of $85.6 mln on strong sales for its hereditary
angioedema treatment, Orladeyo - LSEG data
** Hereditary angioedema is a disorder characterized by
recurrent episodes of severe swelling
** Up to last close, stock down 25.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Recent news on BioCryst Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Carvana, MongoDB
Pharvaris' genetic disorder drug meets main goal in late-stage trial (updated)
Brief: Biocryst Announces Approval Of Orladeyo® For Pediatric Hae Patients In Japan
BioCryst Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Biocryst Pharmaceuticals, - Cash, Cash Equivalents, Restricted Cash And Investments $354 Million At June 30, 2026